GlobalData, April 2011, Pages: 81
HIV/AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData has released its new report, “HIV/AIDS Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Health Alert Communications, Oct 2011, Pages: 84
Death Notifications
Table 8 – Mortality Rates of the First AIDS Cohorts in the United States, 1981
Table 9 – HIV/AIDS Mortality Rates 1981–1985, United States
Table 10 – HIV/AIDS Survival Rates among
STIX Market Research, May 2007, Pages: 116
such as antihypertensives, although they were often reserved for second- or third-line therapy. With the revolution in the survival rates of patients suffering from human immunodeficiency virus (HIV) infection that occurred
VDM Publishing House, July 2009, Pages: 132
This book is motivated to take up exercises on
certain problems pertaining to estimation of
survival function of doubly censored HIV+ data by
using non-parametric and semi-parametric methods
Elsevier Science and Technology, June 2008, Pages: 560
to antiviral agents or host immune responses arise readily, for example, with HIV and influenza.These variations are all of utmost importance for human and animal health as they have prevented us from
Global Industry Analysts, Inc., Oct 2011, Pages: 660
Resistant Bacteria Throws the Spotlight On
Microbial Testing 16
Instant Detection of Pathogens - A New Epoch in the Fight for
Survival 17
Lower Cost Rapid Tests Built on Multiple Sampling Modalities
VDM Publishing House, April 2009, Pages: 104
to survive
and some dissolving completely. Loveness, Makonese.
Loveness Makonese is a Sociologist,specialising in
HIV/AIDS, livelihoods and rural development issues.She holds a
BSc Hons
Degree
VDM Publishing House, May 2010, Pages: 84
Pharmaceutical product patents have recently become the focus of attention for health activists and governments worldwide, largely because of their direct effect on people's lives and survival
John Wiley and Sons Ltd, June 2007, Pages: 384
at a glance.
17.1 Introduction to HIV.
17.2 HIV virion.
17.3 HIV genome.
17.4 HIV-1 replication.
17.5 HIV-1 variability.
17.6 Progression of HIV infection.
17.7 Prevention of HIV transmission
Jain PharmaBiotech, Feb 2012, Pages: 659
Introduction
DNA vaccines for transplantation
Gene therapy for prolonging allograft survival
Gene therapy in lung transplantation
Role of gene therapy in liver transplantation
Gene therapy in kidney
Decision Resources, Inc., Sep 2009, Pages: 36
to survive? What strategies will have better chances of success?
- Burrill & Co.’s CEO has said, “The technology we’ve developed over the last 40 years is great at keeping us alive, but it’s not economically
Bizacumen Inc., Nov 2009, Pages: 353
have initiated sweeping changes in the market for automated and rapid microbiological tests. With probe tests threatening the survival of immunoassay based rapid tests and with advances in automated
Global Markets Direct, Oct 2011, Pages: 101
Positive Phase 1 Safety Data For Its Arcelis Platform In HIV At Keystone Symposia
Jan 31, 2011: Argos Therapeutics Announces Interleukin (IL)-12 Secretion Can Predict Potency Of Arcelis Dendritic Cell (DC
John Wiley and Sons Ltd, June 2008, Pages: 420
Reliability and survival analysis are important applications of stochastic mathematics (probability, statistics and stochastic processes) that are usually covered separately in spite
Global Industry Analysts, Inc., Jan 2011, Pages: 442
Products under Trial
Gene Therapy for Cystic Fibrosis Disease
Gene Therapy for Haemophilia B
Gene Therapy for AIDS/HIV
Gene Therapy for Parkinson’s Disease
The Disease
Therapy
Development
VDM Publishing House, July 2010, Pages: 108
This book gives an understanding of bank securities and the role securities play in the banking industry. Securities management is crucial for the survival of any financial institution in the whole
VDM Publishing House, July 2010, Pages: 152
specialist, accountant, strategist, turnaround specialist, women and child activist, drug and substance activist, HIV/AIDS activist, and a leadership student. He holds a British MBA and a PhD in Banking. He
Jain PharmaBiotech, Feb 2012, Pages: 1008
to induce differentiation of hESCs
Mechanical strain to induce MSC differentiation
Neurotrophin-mediated survival and differentiation of hESCs
Synthetic biology and stem cells
Use of RNAi to expand
RNCOS E-Services Private Limited, Oct 2010, Pages: 150
pediatric vaccines. The rising prevalence of life threatening diseases such as cancer and HIV is the prominent factor driving growth in the adult vaccine segment. A number of healthcare companies are focusing
GBI Research, July 2011, Pages: 132
a rational strategy to stop the functions of cells that rely on these pathways for survival. Non-cancer applications of kinase inhibitors are seen across diseases such as autoimmune diseases, restenosis
